Table 16.
Summary of Janus kinase inhibitors in clinical trials for atopic dermatitis.
| JAK Inhibitor (Administration) | Phase 1 | Approved for AD | JAK1 | JAK2 | JAK3 | TYK2 | SYK |
|---|---|---|---|---|---|---|---|
| Abrocitinib (oral) | 3 | Yes (FDA and EMA) | Yes | - | - | - | - |
| Upadacitinib (oral) | 3 | Yes (FDA and EMA) | Yes | - | - | - | - |
| Baricitinib (oral) | 3 | Yes (FDA and EMA) | Yes | Yes | - | - | - |
| Ruxolitinib (topical) | 3 | Yes (FDA) | Yes | Yes | - | - | - |
| Tofacitinib (topical) | 2a | No | Yes | Yes | Yes | - | - |
| Delgocitinib (topical) | 3 2 | No 2 | Yes | Yes | Yes | Yes | - |
| Gusacitinib (oral) | 2b | No | Yes | Yes | Yes | Yes | Yes |
JAK, Janus kinase; SYK, spleen tyrosine kinase; TYK2, tyrosine kinase 2. 1 Furthest phase achieved in a complete clinical trial; 2 clinical use in Japan.